OncoMatch/Clinical Trials/NCT07106710
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Is NCT07106710 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BCMA CAR-T and GPRC5D/CD3 BiTEs for multiple myeloma, newly diagnosed.
Treatment: BCMA CAR-T · GPRC5D/CD3 BiTEs — This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with ultra-high-risk multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) overexpression
Tumor cells were BCMA and GPRC5D positive
Required: GPRC5D overexpression
Tumor cells were BCMA and GPRC5D positive
Allowed: IGH t(4;14)
t(4;14)
Allowed: IGH t(14;16)
t(14;16)
Allowed: CDKN2C deletion 1p
deletion 1p
Allowed: MYC rearrangement
MYC rearrangement
Allowed: TP53 deletion 17p
deletion 17p
Allowed: TP53 mutation
TP53 mutation
Prior therapy
Cannot have received: BCMA-targeted therapy
Prior BCMA-targeted therapy
Cannot have received: CAR-T cell therapy
Prior CAR-T therapy
Lab requirements
Kidney function
creatinine clearance ≥ 30ml/min (cockroft-gault formula)
Liver function
serum total bilirubin <2 x upper limit of normal (uln), serum ast and alt <3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify